Literature DB >> 7578524

Acquired pure red cell aplasia: a study of six cases.

F Gilsanz1, J Garcia Vela, J A Vargas, J Ibañez, F Oña, J López, M Roggendorf.   

Abstract

Persistent infection by parvovirus B19 associated with pure red cell aplasia (PRCA) has been documented in immunocompromised patients. Bone marrow failure is associated with conditions in which immune surveillance is impaired, and in these instances occult parvovirus infection may be suspected. In this study we have assessed by serological and molecular methods whether parvovirus B19 infection may be a more frequent cause of PRCA than hitherto suspected and whether it may be present in the absence of a typical bone marrow picture. Six patients with PRCA--two with isolated PRCA and no apparent underlying disease, two with a lymphoproliferative disease, one with thymoma, and one with chronic myelomonocytic leukemia--have been studied. Four of the six patients had overt PCRA and were clearly immunocompromised. Parvovirus B19 was not detected in any of the six patients by PCR analysis and serology investigating the presence of IgM or IgG antibodies. Although parvovirus B19 infection needs to be ruled out in PRCA it represents only one, and probably not the most frequent, etiological factor of PRCA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7578524     DOI: 10.1007/BF01910315

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  15 in total

Review 1.  Parvovirus B19 for the hematologist.

Authors:  J W Harris
Journal:  Am J Hematol       Date:  1992-02       Impact factor: 10.047

Review 2.  The biology of pure red cell aplasia.

Authors:  E N Dessypris
Journal:  Semin Hematol       Date:  1991-10       Impact factor: 3.851

3.  Persistent B19 parvovirus infection as a cause of severe chronic anaemia in children with acute lymphocytic leukaemia.

Authors:  G J Kurtzman; B Cohen; P Meyers; A Amunullah; N S Young
Journal:  Lancet       Date:  1988-11-19       Impact factor: 79.321

4.  Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy.

Authors:  G Kurtzman; N Frickhofen; J Kimball; D W Jenkins; A W Nienhuis; N S Young
Journal:  N Engl J Med       Date:  1989-08-24       Impact factor: 91.245

5.  Human parvovirus B19 infection associated with prolonged erythroblastopenia in a leukemic child.

Authors:  H Carstensen; K Ornvold; B J Cohen
Journal:  Pediatr Infect Dis J       Date:  1989-01       Impact factor: 2.129

6.  Prolonged parvovirus B19 infection with severe anaemia in a bone marrow transplant patient.

Authors:  H T Weiland; M M Salimans; W E Fibbe; P M Kluin; B J Cohen
Journal:  Br J Haematol       Date:  1989-02       Impact factor: 6.998

7.  Chronic bone marrow failure due to persistent B19 parvovirus infection.

Authors:  G J Kurtzman; K Ozawa; B Cohen; G Hanson; R Oseas; N S Young
Journal:  N Engl J Med       Date:  1987-07-30       Impact factor: 91.245

8.  Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS.

Authors:  N Frickhofen; J L Abkowitz; M Safford; J M Berry; J Antunez-de-Mayolo; A Astrow; R Cohen; I Halperin; L King; D Mintzer
Journal:  Ann Intern Med       Date:  1990-12-15       Impact factor: 25.391

9.  Diagnosis of human parvovirus B19 infections by polymerase chain reaction.

Authors:  T F Schwarz; G Jäger; W Holzgreve; M Roggendorf
Journal:  Scand J Infect Dis       Date:  1992

10.  Parvovirus B19 as a cause of acquired chronic pure red cell aplasia.

Authors:  N Frickhofen; Z J Chen; N S Young; B J Cohen; H Heimpel; J L Abkowitz
Journal:  Br J Haematol       Date:  1994-08       Impact factor: 6.998

View more
  2 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Immunosuppressive treatment in patient with pure red cell aplasia associated with chronic myelomonocytic leukemia: harm or benefit?

Authors:  Saloni Tanna; Celalettin Ustun
Journal:  Int J Hematol       Date:  2009-09-18       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.